GENFF 주가 차트
GENFF 재무
Genflow Biosciences plc
$0.02
-24.64%
$0
종가: Jun 23, 16:00:00 GMT-4
$0.02
0%
$0
애프터마켓: Jun 23, 20:00:00 GMT-4
뒤로
Genflow Biosciences plc (GENFF) 재무
수입
자산 및 부채 명세서
현금 흐름
연간
분기별
GENFF 소득
미화 수백만 달러. 회계 연도는 2월부터 1월까지입니다.
Follow-Up Questions
Genflow Biosciences plc의 주요 재무제표는 무엇인가요?
GENFF의 주요 재무 비율은 무엇인가요?
Genflow Biosciences plc의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Genflow Biosciences plc은 수익성이 있나요?
Genflow Biosciences plc에 부채가 있나요?
Genflow Biosciences plc의 발행 주식은 몇 주인가요?
주요 통계
이전 종가
$0.0284
시가
$0.0397
일일 범위
$0.0214 - $0.0397
52주 범위
-
거래량
--
평균 거래량
--
배당수익률
--
EPS(TTM)
--
시가총액
--
Genflow Biosciences Plc란 무엇인가요?
Genflow Biosciences Plc operates as a biotechnology company, which engages in the research and development of gene therapies to counteract the effects of aging and diseases associated with advanced age. The firm is engaged in developing gene therapies designed to target the aging process and to reduce and delay the incidence of age-related diseases, which is done through therapeutics targeting aging in humans by using adeno-associated virus (AAV) vectors to deliver copies of the Sirtuin-6 (SIRT6) gene variant that is found in centenarians into cells. The firm's product pipeline includes GF-1002, GF-1003, GF-1004, GF-1005 and GF-1006. GF-4001. GF-1002 is a suspension of an adeno-associated viral vector-based gene therapy for intravenous infusion. GF-1004 is a non-human version of GF-1002 anti-ageing gene therapy developed for veterinary use (dogs). GF-1003 is a formulation of an adeno-associated viral vector-based gene therapy. The firm has operations in the United Kingdom and Belgium.
